---
provider: claude_code
model: claude-haiku-5-5, claude-opus-5-5
cached: false
start_time: '2026-11-10T18:31:32.551781'
end_time: '2026-11-10T18:38:35.959503'
duration_seconds: 423.41
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: EFEMP2-Related Cutis Laxa
  mondo_id: MONDO:0013754
  category: Mendelian
  causal_genes: EFEMP2
  omim_id: OMIM:614437
  synonyms: ARCL1B
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-5-5
  - claude-opus-5-5
  web_search_requests: 1
  num_turns: 26
  total_cost_usd: 3.1652117000000004
  session_id: 0d6bc76e-b117-4f72-a510-ff7d1e66125f
  stop_reason: end_turn
  permission_denials: 6
  denied_tools:
  - Bash
  - Write
  assistant_text_blocks: 6
citation_count: 6
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** EFEMP2-Related Cutis Laxa
- **MONDO ID:** MONDO:0013754 (if available)
- **Causal gene(s):** EFEMP2
- **OMIM:** OMIM:614437
- **Synonyms:** ARCL1B
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **EFEMP2-Related Cutis Laxa** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output


# EFEMP2-Related Cutis Laxa (ARCL1B): research report

**Target:** EFEMP2-Related Cutis Laxa · MONDO:0013754 · OMIM:614437 · causal gene **EFEMP2** (fibulin-4, alias FBLN4; HGNC:3219; chromosome 11q13)
**Retrieved:** 2026-11-10. Quotes come from PubMed abstracts fetched with NCBI E-utilities, from the GeneReviews abstract served by Europe PMC, and from the local ClinGen export `cache/clingen/gene_validity.csv`.

---

## 1. Disease information

**Overview.** EFEMP2-related cutis laxa is an autosomal recessive connective tissue disorder caused by biallelic loss-of-function variants in **EFEMP2**, which encodes the extracellular matrix glycoprotein fibulin-4. Fibulin-4 is needed to build elastic fibers and cross-link them. The main problem is in the large elastic arteries: aortic aneurysm, arterial elongation, tortuosity and stenosis. Lax skin, emphysema, hernias and skeletal fragility vary from patient to patient. Disease ranges from death before or shortly after birth to isolated aortopathy with no skin signs at all.

- GeneReviews (Loeys, De Paepe, Urban; PMID:21563328; Europe PMC lists first publication and last revision both as 2023-06-15): *"EFEMP2-related cutis laxa, or autosomal recessive cutis laxa type 1B (ARCL1B), is characterized by cutis laxa and systemic involvement, most commonly arterial tortuosity, aneurysms, and stenosis; retrognathia; joint laxity; and arachnodactyly. Severity ranges from perinatal lethality as a result of cardiopulmonary failure to manifestations limited to the vascular and craniofacial systems."*
- MONDO definition (OLS4): *"An autosomal recessive cutis laxa type I characterized by disturbed elastic fiber formation resulting in severe systemic connective tissue abnormalities that has material basis in homozygous or compound heterozygous mutation in the EFEMP2 gene on chromosome 11q13."*

**Identifiers**

| System | ID | Status |
|---|---|---|
| MONDO | MONDO:0013754 "cutis laxa, autosomal recessive, type 1B" | verified (OLS4) |
| OMIM | OMIM:614437 | verified (MONDO xref) |
| DOID | DOID:0070133 | verified (MONDO xref) |
| GARD | GARD:0015804 | verified (MONDO xref) |
| MedGen / UMLS | MEDGEN:482428 / UMLS:C3280798 | verified (MONDO xref) |
| GeneReviews | PMID:21563328 (NBK54469) | PMID verified; the NBK URL returned a browser-check page, so I haven't confirmed it |
| Orphanet | Probably filed under *Autosomal recessive cutis laxa type 1* (ORPHA:90350) | **not verified**: search returned no Orphanet page |
| ICD-10 | Q82.8 (other specified congenital malformations of skin) is the usual code for congenital cutis laxa | **not verified** |
| ClinGen | EFEMP2 / MONDO:0013754, AR, **Definitive**, Hereditary Cardiovascular Disease GCEP, 2024-08-23, `CGGV:assertion_8911130f-a1fc-4404-8905-5632a49a95fe-2024-08-23T160000.000Z` | verified (local ClinGen CSV) |

**Synonyms:** ARCL1B; cutis laxa, autosomal recessive, type IB; fibulin-4 deficiency; FBLN4-related cutis laxa. A recessive aortopathy is also described with no skin signs, sometimes called "recessively inherited aortic aneurysm" (PMID:22440127). The Kerala cohort was described as a "lethal arteriopathy syndrome" (PMID:22943132).

**Source type.** The evidence is aggregated case reports and case series, roughly 60–80 published individuals by 2024. The 22-infant Kerala series and the 9-patient Saudi family series are the largest. There is no EHR-derived or registry data.

---

## 2. Etiology

- **Cause.** Biallelic (homozygous or compound heterozygous) pathogenic EFEMP2 variants. The condition is monogenic and fully genetic.
- **Genetic risk factors.** Consanguinity is the main risk factor. Founder alleles drive local clusters: p.Asp203Ala in South India (PMID:22943132) and p.Glu161Lys in Saudi Arabia (PMID:22440127, PMID:39489349).
- **Modifier genes.** EFEMP2 itself has been proposed as a modifier. A heterozygous fibulin-4 variant was suggested to modify the phenotype in a family with recessive *ELN* cutis laxa (PMID:19194475; this is a title-level claim and I have not read the abstract). No modifier of ARCL1B itself is established.
- **Environmental risk and protective factors.** None is documented. GeneReviews recommends avoiding sun tanning (skin) and cigarette smoking (emphysema). These are tertiary-prevention measures, not etiologic factors.
- **Gene-environment interaction.** Not studied in humans. Mouse work shows that mechanical stretch and angiotensin II drive aneurysm signaling, and fibulin-4 loss makes smooth muscle cells more sensitive to both (PMID:30355232). That makes hemodynamic load a plausible but unproven modifier.

---

## 3. Phenotypes

Frequencies come from the Kerala p.Asp203Ala cohort (n=22; PMID:22943132) unless stated otherwise. Other cohorts differ, and in some, such as the Saudi p.Glu161Lys families, skin laxity is absent. The HPO IDs below are **suggestions recalled from memory and must be looked up before binding.**

| Phenotype | Suggested HPO | Onset / course | Frequency / notes | Key PMID |
|---|---|---|---|---|
| Ascending aortic aneurysm / aortic root dilatation | HP:0004970 Ascending tortuous aorta?; HP:0002616 Aortic root aneurysm; HP:0004942 Aortic aneurysm | congenital to infancy, progressive | near-universal; Z-scores 5–33 (PMID:22440127) | 16685658, 20389311, 22440127 |
| Arterial tortuosity / elongation | HP:0005116 Arterial tortuosity | congenital | very frequent | 22943132, 22070778, 23212998 |
| Arterial / pulmonary artery stenosis or occlusion | HP:0100545 Arterial stenosis; HP:0004415 Pulmonary artery stenosis | neonatal | frequent; occlusion was fatal at 27 days (PMID:17937443) | 17937443, 20389311 |
| Aortic isthmus hypoplasia | HP:0012304 Hypoplastic aortic arch? | congenital | 9/22; "correlated with early death (≤4 months)" | 22943132 |
| Cutis laxa | HP:0000973 Cutis laxa | congenital | 52% (Kerala); absent in all 9 Saudi patients | 22943132, 22440127 |
| Pulmonary emphysema | HP:0002097 Emphysema | infancy ("developmental emphysema") | variable | 16685658 |
| Long philtrum / thin vermilion | HP:0000343 / HP:0000233 | congenital | 90% | 22943132 |
| Retrognathia / micrognathia | HP:0000278 / HP:0000347 | congenital | 43%; can obstruct the airway, sometimes needing tracheostomy | 22943132, 21563328 |
| Hypertelorism | HP:0000316 | congenital | 57% | 22943132 |
| Prominent eyes; sagging cheeks | HP:0000520 / HP:0100678? | congenital | 43% each | 22943132 |
| Arachnodactyly / long slender digits | HP:0001166 | congenital | 48% | 22943132, 19664000 |
| Visible arterial pulsations | none known | infancy | 38% | 22943132 |
| Joint laxity | HP:0001388 | childhood | common | 16685658 |
| Bone fractures at birth / OI-like fragility | HP:0002757 Recurrent fractures; HP:0011398? | prenatal / neonatal | subset; prenatal fractures in twins | 16685658, 22070778, 30140196 |
| Inguinal / diaphragmatic / hiatal hernia | HP:0000023 / HP:0000776 / HP:0002036 | neonatal | subset | 16685658, 30140196, 19664000 |
| Pectus excavatum | HP:0000767 | childhood | subset | 16685658 |
| Contractures, clubfoot, wormian bones, bowed long bones | HP:0001371, HP:0001762, HP:0002645, HP:0006487 | prenatal | severe/fetal cases | 30140196, 19664000 |
| Soft-tissue / vascular bleeding (vessel fragility) | HP:0001892? | perinatal | lethal case | 19664000 |
| Overgrowth, microcephaly | HP:0001548 / HP:0000252 | prenatal | single case | 19664000 |
| Keratoglobus / corneal rupture | HP:0011490? | adult (38 y) | single case | 31194159 |
| Baroreflex failure, thunderclap headache, cerebral vasospasm | none known | childhood | single case | 24733866 |
| Upper airway obstruction from aneurysm compression | HP:0002781? | infancy | case | 24276535 |

Key quotes:
- PMID:16685658: *"She had multiple bone fractures at birth and was diagnosed with cutis laxa, vascular tortuosity, ascending aortic aneurysm, developmental emphysema, inguinal and diaphragmatic hernia, joint laxity, and pectus excavatum by age 2 years."*
- PMID:22943132: *"The phenotype included a variable combination of cutis laxa (52%), long philtrum-thin vermillion (90%), micrognathia (43%), hypertelorism (57%), prominent eyes (43%), sagging cheeks (43%), long slender digits (48%), and visible arterial pulsations (38%)."*
- PMID:20389311: *"patients with recessive FBLN4 mutations are predominantly characterized by aortic aneurysms, arterial tortuosity and stenosis."*
- PMID:22440127: *"The skin manifestations of cutis laxa were not found in any patient."*
- PMID:30140196 (fetal): *"Anomalies included cutis laxa, arachnodactyly, clubfoot, wormian bones, moderate bowing of long bones with slender bone trabeculae, rib fractures, undermuscularized diaphragm, hiatal hernia, and arterial tortuosity with thick vascular walls and disorganized elastic fibers."*

**Laboratory and histological findings.** Skin elastic fibers are underdeveloped, sparse or fragmented (PMID:16685658, PMID:17937443). The aortic media shows cystic medial degeneration and elastic fiber fragmentation (PMID:19664000, PMID:42404516). Patient fibroblasts and aortic wall carry less fibulin-4, and pSmad2/CTGF staining is increased (PMID:20389311).

**Quality of life.** No formal QoL studies exist (EQ-5D, SF-36 and similar). The burden comes from repeated cardiovascular surgery, airway compromise and lifelong imaging surveillance.

---

## 4. Genetic / molecular information

- **Gene.** EFEMP2 (fibulin-4; HGNC:3219; NCBI Gene 30008, not verified). 11q13. It is a short fibulin with tandem calcium-binding EGF-like (cbEGF) domains and a C-terminal fibulin domain.
- **Inheritance.** Autosomal recessive. ClinGen rates the gene-disease pair AR Definitive (2024-08-23).
- **Variant classes** (all germline):
  - Missense, the most common class. Examples: p.Glu57Lys (c.169G>A), the first and a recurrent allele (PMID:16685658). p.Glu126Lys, p.Ala397Thr, p.Glu126Val (PMID:20389311). p.Cys267Tyr (PMID:19664000). p.Arg279Cys (PMID:17937443). p.Glu161Lys, the Saudi founder (PMID:22440127). p.Asp203Ala (c.608A>C), the South Indian founder (PMID:22943132). p.Arg227Cys. p.Tyr155Ser (c.464A>C) (PMID:39764439).
  - Frameshift: c.1070_1073dupCCGC, subject to NMD (PMID:17937443); c.577delC (PMID:20389311).
  - Nonsense: c.639C>A p.Cys213* (PMID:30140196); a homozygous premature stop codon in MZ twins (PMID:22070778).
- **Functional consequence: loss of function**, by several routes:
  - Impaired secretion or ER retention: E57K dimerizes, is inefficiently secreted and triggers ER stress (PMID:26178373). E126K and C267Y also impair secretion (PMID:27339457).
  - Disrupted binding to partners: E126K binds collagen IV, fibrillin-1, LTBP1 and LTBP4 less well. A397T loses LTBP1 binding. E57K reduces binding to the LOX propeptide (PMID:27339457).
  - Null alleles through NMD (PMID:17937443).
  - PMID:27339457: *"different mutations in the fibulin-4 gene result in different molecular defects affecting secretion rates, protein stability, LOX-induced cross-linking, or binding to other ECM components and molecules of the TGF-β pathway"*.
- **Genotype-phenotype.** Truncating alleles tend toward fetal or perinatal lethality (PMID:30140196, PMID:22070778). p.Asp203Ala homozygosity is usually lethal (17/21 died, median age 4 months). p.Glu161Lys gives aortopathy without skin laxity and has survivors into adulthood. These are cohort-level observations; no formal correlation study has been done.
- **Heterozygous / dominant claims (disputed).** A heterozygous p.Arg83Cys was reported in a family with dominant nonsyndromic thoracic aortic aneurysm, based on in-silico evidence only (PMID:38113391). Treat this as unconfirmed. ClinGen's Definitive call is for AR only. In mouse, a modest dose reduction (Fibulin-4+/R) "occasionally resulted in small aneurysm formation" (PMID:17293478).
- **Allele frequency.** Not retrieved from gnomAD (**not checked**). The founder alleles are expected to be enriched in Kerala and Saudi populations.
- **Epigenetics and chromosomal abnormalities.** None reported.

---

## 5. Environmental information

Not applicable as a cause: there are no known toxins, infectious agents or lifestyle triggers. Advice to avoid smoking and sun tanning is for managing complications (GeneReviews).

---

## 6. Mechanism / pathophysiology

### Ordered causal chain

1. **Biallelic EFEMP2 loss-of-function variants** reduce or remove functional extracellular fibulin-4, through NMD, ER retention or secretion failure, or loss of binding (PMID:17937443, PMID:26178373, PMID:27339457). *Demonstrated in patient fibroblasts and recombinant protein.*
2. **Lysyl oxidase (LOX) is not recruited or activated properly.** Fibulin-4 binds the LOX propeptide and tethers LOX to tropoelastin (PMID:19855011). It is also needed to transfer copper from ATP7A to LOX in the trans-Golgi network, and without that transfer the LTQ cofactor does not form (PMID:33239290). LOX processing is impaired in E57K skin and in Fbln4−/− bone (PMID:26178373, PMID:26690653). *Demonstrated in mouse and in vitro.*
3. **Elastin and collagen cross-linking falls, and elastic fiber assembly is defective.** Null mice "do not develop intact elastic fibers but contain irregular elastin aggregates" and "elastin cross-links in fibulin-4-/- tissues were largely diminished" (PMID:16478991). Collagen fibrils become abnormal in aorta, skin, tendon and bone (PMID:26220971, PMID:26178373, PMID:26690653).
   - *Caveat:* in Fbln4 E57K mice, elastin cross-linking was normal in arteries (PMID:28508064), and in SMKO aorta elastin cross-linking was unaffected (PMID:26220971). So reduced LOX-mediated cross-linking is not the whole vascular mechanism.
4. **Branch A (connective tissues):** fragmented, sparse elastic fibers lead to **cutis laxa** (dermis), **emphysema** (lung parenchyma), hernias and joint laxity. Defective collagen cross-linking leads to **bone fragility, fractures and tendon contractures** (PMID:26690653, PMID:26711913).
5. **Branch B (aortic wall).** Smooth muscle cells lose their connections to the elastic laminae, and the elastin-contractile unit breaks down (PMID:26486174, PMID:30355232).
6. The **smooth muscle cells then fail to differentiate fully.** Contractile gene expression falls, they proliferate, and ERK1/2 signaling rises (PMID:20019329). *Mouse.*
7. **Abnormal mechanosensing sets off a signaling cascade.** Thrombin, MMP-9 and stretch activate PAR1, which induces Egr1 (PMID:32580633). Egr1 induces ACE, which drives local angiotensin II signaling (PMID:23636094) and induces Thbs1 (PMID:30355232). AngII acts through PI3K to raise SSH1, which activates cofilin and remodels the actin cytoskeleton (PMID:26486174). *Mouse, with PAR1/Egr1/thrombin and Thbs1 confirmed in human TAA tissue.*
8. **TGF-β signaling rises** (pSmad2, CTGF; TGF-β2 especially). This is shown in patient aortic and lung tissue (PMID:20389311) and in mouse smooth muscle cells (PMID:26607280, PMID:17293478). Downstream effects include lower PGC1α, reduced mitochondrial respiration and more ROS (PMID:29931197), and smooth muscle senescence with a SASP (PMID:38902222). *Whether TGF-β is a driver or a compensatory change is unresolved.*
9. **Medial degeneration and aneurysm follow.** Cystic medial degeneration, elastic fiber fragmentation and smooth muscle loss (PMID:21858106) produce **ascending aortic aneurysm, arterial elongation and tortuosity, and stenosis**. Ultimately rupture, dissection or cardiopulmonary failure can occur. Hypertension and aortic valve disease add to the load (PMID:28508064, PMID:17293478, PMID:36565192).
10. **The conduit-artery selectivity** is explained by FBLN4 being required mainly in large elastic arteries, while vessel wall structure in muscular arteries is normal (PMID:28508064).

Key quotes:
- PMID:19855011: *"These data suggest a mechanism of elastogenesis, in which a sufficient amount of FBLN4 is essential for tethering LOX to tropoelastin to facilitate cross-linking."*
- PMID:33239290: *"Our studies showed that fibulin-4 is required for copper ion transfer from the copper transporter ATP7A to LOX in the trans-Golgi network (TGN), which is a necessary step for LTQ formation."*
- PMID:20389311: *"pSmad2 and CTGF immunostaining of aortic and lung tissue revealed an increase in transforming growth factor (TGF)beta signaling."*
- PMID:26486174: *"These results suggest that aneurysm formation arises from abnormal mechanosensing of SMCs resulting from the loss of elastic lamina-SMC connections and from increased SSH1 and cofilin activity"*

### Suggested ontology terms (all **unverified**; look each up before binding)

- **GO BP:** elastic fiber assembly (GO:0048251); collagen fibril organization (GO:0030199); peptidyl-lysine oxidation / protein-lysine 6-oxidase activity of LOX (GO:0004720, MF); transforming growth factor beta receptor signaling pathway (GO:0007179); ERK1 and ERK2 cascade (GO:0070371); angiotensin-activated signaling pathway (GO:0038166); smooth muscle cell differentiation (GO:0051145); response to endoplasmic reticulum stress (GO:0034976); cellular senescence (GO:0090398); actin cytoskeleton organization (GO:0030036); copper ion transport (GO:0006825).
- **GO CC:** elastic fiber (GO:0071953); extracellular matrix (GO:0031012); trans-Golgi network (GO:0005802).
- **CL:** aortic smooth muscle cell (CL:0002539); vascular smooth muscle cell (CL:0000359); fibroblast of dermis (CL:0002551); endothelial cell of aorta?; osteoblast (CL:0000062); chondrocyte.
- **CHEBI:** desmosine; copper(2+); angiotensin II; losartan (CHEBI:6541?).

### Molecular profiling

Aortic transcriptomes and proteomes are published for Fibulin-4+/R and R/R mice (PMID:17293478, PMID:29931197), SMKO aortas from P1 to P30 (PMID:26486174), late-embryonic and newborn aorta arrays (PMID:30312140) and DKO valve RNA-seq (PMID:36565192). No human omics, single-cell or CRISPR-screen data were found. I did not search GEO accessions.

---

## 7. Anatomical structures affected

- **Primary:** ascending aorta and aortic root (UBERON:0001496 ascending aorta), aortic arch and isthmus, pulmonary trunk and arteries, carotid, iliac and other elastic conduit arteries; dermis (UBERON:0002067); lung parenchyma and alveoli.
- **Secondary:** heart (left ventricular dilation and aortic regurgitation in mice; valve thickening), diaphragm (hernia, undermuscularized), skeleton (long bones, ribs, skull fractures), tendons and joints, inguinal canal, cornea (one case), upper airway (compression, retrognathia).
- **Systems:** cardiovascular (dominant), integumentary, respiratory, musculoskeletal, craniofacial.
- **Subcellular:** extracellular matrix and elastic fiber; ER (retention of mutant protein); trans-Golgi network (copper loading of LOX).
- **Laterality:** systemic and bilateral.

---

## 8. Temporal development

- **Onset:** congenital, often detectable prenatally from the second trimester, with tortuous dilated aorta, pulmonary atresia, fractures and clubfoot (PMID:30140196, PMID:38923535). In the Kerala cohort, median age at presentation was 1.5 months. A milder group comes to attention in childhood or is found as an asymptomatic adult on family screening (PMID:22440127; median age of onset of thoracic aortic dilatation 4.5 years in the Saudi pediatric cohort, PMID:39489349).
- **Course:** lifelong. The aortic aneurysm progresses, and redo surgery is often needed (PMID:36518920, PMID:24276535).
- **Critical window:** in mice, angiotensin blockade works only *"within a narrow therapeutic window during the first month of life"* (PMID:23636094). Prenatal losartan prevented elastic fiber fragmentation, while postnatal losartan improved survival without fixing wall structure (PMID:21858106). Whether a similar window exists in humans is unknown.
- **Remission:** none.

---

## 9. Inheritance and population

- **Pattern:** autosomal recessive (HP:0000007). Penetrance appears complete for biallelic genotypes, but expressivity varies widely, including within families (PMID:22440127: *"Intrafamilial variability was also evident"*). Heterozygous carriers are asymptomatic according to GeneReviews. The dominant claim in PMID:38113391 is unconfirmed.
- **Prevalence:** not established; ultra-rare. Literature cases number in the dozens, likely fewer than 100 (my estimate from the case literature, not a sourced figure). Orphanet prevalence was not retrieved.
- **Founder effects:** p.Asp203Ala in South India (Kerala): *"Genetic studies revealed an identical c.608A > C (p. Asp203Ala) mutation in exon 7 of the FBLN4 gene in all 22 patients, homozygous in 21"*. p.Glu161Lys in Saudi Arabia: a homozygous EFEMP2 variant was found in 6 of 13 genetically solved childhood TAD families (46.2%; PMID:39489349).
- **Consanguinity:** common. 8 of 22 Kerala families; all 4 Saudi families in PMID:22440127.
- **Sex ratio:** 11 males and 11 females in the Kerala cohort; no sex bias is expected.
- **Carrier frequency:** not established (gnomAD not checked).

---

## 10. Diagnostics

- **Clinical criteria:** none formalized. GeneReviews: *"The diagnosis of EFEMP2-related cutis laxa is established in a proband with suggestive findings and biallelic pathogenic variants in EFEMP2 identified by molecular genetic testing."*
- **Imaging:** echocardiography (aortic root and ascending aorta Z-scores), CT or MR angiography head to pelvis to map tortuosity, stenosis and aneurysms (radiologic phenotype described in PMID:24838734), and prenatal ultrasound (PMID:30140196, PMID:38923535).
- **Histology:** skin biopsy shows reduced or fragmented elastic fibers. Aortic specimens show medial degeneration and elastic fiber fragmentation.
- **Fibroblast studies (research use):** reduced fibulin-4 in the medium or ECM and increased pSmad2 (PMID:20389311, PMID:17937443).
- **Genetic testing:** multigene panels for cutis laxa or heritable thoracic aortic disease (EFEMP2, FBLN5, LTBP4, ELN, ATP6V0A2, PYCR1, ALDH18A1, ATP7A, FBN1, TGFBR1/2, SMAD3, SLC2A10 and others), or exome/genome sequencing. Exome sequencing solved delayed or misdiagnosed cases (PMID:39764439, where the child was first misdiagnosed with Takayasu arteritis) and prenatal cases (PMID:38923535). Targeted founder-variant testing makes sense in Kerala and Saudi populations. CMA, karyotype, mtDNA and repeat testing have no role.
- **Differential diagnosis:**
  - Arterial tortuosity syndrome (SLC2A10): tortuosity without emphysema, normal elastogenesis genes.
  - FBLN5-related ARCL1A and LTBP4-related ARCL1C: *"FBLN5 and LTBP4 mutations cause a very similar phenotype associated with severe pulmonary emphysema, in the absence of vascular tortuosity or aneurysms"* (PMID:22829427).
  - ELN-related cutis laxa (AD and AR).
  - Loeys-Dietz syndrome (TGFBR1/2, SMAD3, TGFB2/3).
  - Marfan syndrome (FBN1).
  - EMILIN1 arterial tortuosity-bone fragility syndrome (PMID:36351433).
  - Osteogenesis imperfecta, for the fracture-predominant fetal presentation (PMID:22070778).
  - ARCL2 / ATP6V0A2, PYCR1, ALDH18A1 forms; occipital horn syndrome / ATP7A; LTBP1-related cutis laxa (PMID:33991472).
  - Takayasu arteritis, as an acquired mimic (PMID:39764439).
- **Screening:** cascade carrier testing; prenatal diagnosis and PGT when familial variants are known; echocardiographic screening of siblings (PMID:22440127 found affected sibs aged 17 and 20 this way). No newborn screening exists.

---

## 11. Outcome / prognosis

- **Mortality:** high in early-onset and founder-lethal forms. Kerala: *"Homozygosity was lethal (17/21 died, median age 4 months). Isthmic hypoplasia (n = 9) correlated with early death (≤4 months)."* Perinatal deaths and terminations are reported for truncating alleles (PMID:19664000, PMID:22070778, PMID:30140196, PMID:17937443).
- **Survivors:** longer-term survival after surgery is reported (PMID:23532871). In the Saudi childhood-TAD cohort (PMID:39489349) all patients were alive at 3–31 years. That cohort mixes genes and is a high-intervention setting.
- **Complications:** aneurysm rupture or dissection, airway compression, respiratory failure from emphysema, need for redo aortic surgery, baroreflex failure (PMID:24733866), cerebral vasospasm.
- **Prognostic factors:** isthmic hypoplasia; genotype (truncating or p.Asp203Ala more severe than p.Glu161Lys); prenatal presentation. No biomarkers have been validated.

---

## 12. Treatment

No disease-specific therapy exists, and no trials were found on ClinicalTrials.gov (I didn't run a separate search, but none turned up in the literature).

| Intervention | Evidence | Suggested NCIT | `therapeutic_modality` |
|---|---|---|---|
| Angiotensin II receptor blocker (losartan) for aortic dilatation | GeneReviews; case use (PMID:24276535); mouse: prevents aneurysm in an early window (PMID:23636094), improves survival (PMID:21858106, PMID:26828783) | NCIT:C15986 Pharmacotherapy; agent losartan (CHEBI) | SMALL_MOLECULE |
| Beta-blocker | GeneReviews; case use (PMID:24276535); propranolol had no effect in Fibulin-4R/R mice (PMID:26828783) | NCIT:C15986 | SMALL_MOLECULE |
| ACE inhibitor (captopril) | mouse only (PMID:23636094) | NCIT:C15986 | SMALL_MOLECULE |
| Ascending aorta, root or arch replacement; valve-sparing root and total arch; two-stage elephant trunk | PMID:24276535, PMID:28673110, PMID:36518920, PMID:42404516, PMID:29362193 | NCIT:C15329 Surgical Procedure | SURGERY |
| Hernia repair | GeneReviews | NCIT:C15329 | SURGERY |
| Tracheostomy for retrognathia-related airway obstruction | GeneReviews | needs lookup | SURGERY |
| Symptomatic emphysema management | GeneReviews | NCIT:C15747 Supportive Care | OTHER |
| Muscle-reinforcing physical therapy for joint hypermobility | GeneReviews | NCIT:C15302 Physical Therapy | BEHAVIORAL |
| Genetic counseling | GeneReviews | NCIT:C15240 Genetic Counseling | — |

GeneReviews management (verbatim): *"Treatment of aortic root dilatation with beta-blockers or angiotensin receptor inhibitors can be considered. Aortic aneurysm replacement has been performed successfully. Symptomatic treatment of pulmonary emphysema; muscle-reinforcing physical therapy for joint hypermobility; routine repair of hernias. Tracheostomy may be necessary when retrognathia leads to upper-airway obstruction."*

**Experimental and preclinical targets (mouse only):** PI3K inhibitors (PMID:26486174), Thbs1 deletion (PMID:30355232), Egr1/PAR1 (PMID:32580633), PGC1α activation (PMID:29931197), JAK/STAT or TGF-β inhibition and senolytics in vitro (PMID:38902222). No gene therapy exists.

---

## 13. Prevention

- **Primary:** carrier testing, prenatal diagnosis and PGT in at-risk families (GeneReviews). Founder-variant awareness in Kerala and Saudi populations.
- **Secondary:** echocardiographic screening of siblings.
- **Tertiary** (GeneReviews): *"Follow-up evaluations with a cardiologist and pulmonologist at least annually starting from the time of diagnosis. Annual MR angiography from head to pelvis. Agents/circumstances to avoid: Sun tanning to avoid damaging the skin; cigarette smoking to avoid worsening of emphysema."*
- **Counseling:** *"each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."*
- No vaccines or public-health measures apply.

---

## 14. Other species / natural disease

No naturally occurring animal EFEMP2 disease was found (I didn't search OMIA directly). EFEMP2 is conserved across vertebrates. The mouse ortholog is *Efemp2* (Fbln4); I haven't confirmed the MGI or NCBI Gene IDs. No zoonotic relevance.

---

## 15. Model organisms (all *Mus musculus*, NCBITaxon:10090)

| Model | Recapitulates | Limitations | PMID |
|---|---|---|---|
| **Fbln4−/− (germline null)** | no intact elastic fibers, emphysema, arterial tortuosity, aneurysm, rupture; forelimb contractures; abnormal collagen and LOX activation in bone | perinatal lethal, so postnatal course can't be studied; more severe than most human missense genotypes | 16478991, 26690653, 26711913, 33239290 |
| **Fibulin-4 R/R hypomorph (4-fold reduced) and +/R (2-fold)** | ascending aortic dilatation, tortuous stiff aorta, valve stenosis/insufficiency, cystic medial degeneration, raised TGF-β, death around 3 months; emphysema | the hypomorph came from targeting *Mus81*, so it is a dosage model, not a patient allele | 17293478, 21858106, 25255451, 29931197, 38902222 |
| **Fbln4 SMKO (SM22-Cre)** | postnatal ascending aortic aneurysm; smooth muscle immaturity; ACE/AngII, Egr1, Thbs1 and cofilin pathways; losartan/captopril prevention | smooth muscle–restricted, so no skin, lung or bone phenotype | 20019329, 23636094, 26486174, 30355232, 32580633 |
| **Fbln4 E57K knock-in** (human allele) | survives to adulthood with loose skin, bent forelimb, aortic aneurysm, tortuosity, emphysema, hypertension; ER stress; abnormal collagen fibrils; conduit-artery selectivity | arterial elastin cross-linking normal, which conflicts with the LOX model | 26178373, 28508064, 37267118 |
| **Fbln4 EC + SMC double KO** | worse aneurysm, aortic valve thickening, EndMT | genetic overlay with no direct patient counterpart | 36565192 |
| **Fbln4 dose series (SM-Cre graded)** | dose-dependent stiffness, then aneurysm | — | 19855011 |

PMID:26178373: *"The mutant mice survived into adulthood and displayed abnormalities in multiple organ systems, including loose skin, bent forelimb, aortic aneurysm, tortuous artery, and pulmonary emphysema."*

The E57K knock-in is the best model of a patient allele. The SMKO line is the workhorse for aneurysm mechanism and drug work. No zebrafish, iPSC or organoid models were found. Human aortic endothelial knockdown (PMID:36565192) and HEK293 recombinant mutant studies (PMID:27339457) are the in-vitro systems.

---

## Gaps and cautions for curation

1. **The LOX cross-linking model conflicts across studies.** PMID:16478991 reports elastin cross-links "largely diminished" in null mice. PMID:28508064 and PMID:26220971 found arterial elastin cross-linking normal. Worth a `KNOWLEDGE_GAP` or two-sided evidence on the LOX node.
2. **TGF-β: driver or marker?** The rise is documented in humans and mice, but a causal role isn't shown. Avoid TRIGGERS-style predicates.
3. **Nearly all mechanism evidence downstream of the elastic fiber defect is mouse** (`MODEL_ORGANISM`). Human support covers only the elastic fiber defect, reduced fibulin-4 and pSmad2/CTGF.
4. **The dominant-TAA report (PMID:38113391) rests on in-silico evidence.** If it is included, a `DISPUTED` genetic row fits better than a subtype.
5. **Not verified, so don't bind as written:** the Orphanet code, ICD codes, every HPO/GO/CL/CHEBI ID in the tables above, NCBI Gene and MGI IDs, gnomAD frequencies, and the NBK accession.
6. **Next steps:** the draft `kb/disorders/EFEMP2-Related_Cutis_Laxa.yaml` is a stub (23 lines). Its `association: Causative` field is not a schema slot; the schema uses `relationship_type: CAUSATIVE`. Cited PMIDs need `just fetch-reference`. Only PMID:22829427 and PMID:23954411 are already in `references_cache/`.

---

### Sources
- PubMed abstracts via NCBI E-utilities: PMIDs 16685658, 16478991, 17937443, 19664000, 20389311, 22943132, 22829427, 24276535, 20019329, 19855011, 17293478, 23636094, 26178373, 26220971, 26690653, 33239290, 27339457, 21858106, 26828783, 22070778, 23212998, 22440127, 30140196, 39764439, 38113391, 24733866, 31194159, 42404516, 38923535, 30355232, 26486174, 32580633, 29931197, 38902222, 26607280, 28508064, 24613575, 36565192, 39489349
- GeneReviews abstract (PMID:21563328) via [Europe PMC REST](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21563328&resultType=core&format=json)
- MONDO record via [OLS4](https://www.ebi.ac.uk/ols4/api/ontologies/mondo/terms?obo_id=MONDO:0013754)
- ClinGen gene-disease validity: local `cache/clingen/gene_validity.csv`
- Web search leads (secondary): [GeneReviews clinical description](https://https.ncbi.nlm.nih.gov/books/n/gene/efemp2-cutis-laxa/), [MedlinePlus EFEMP2](https://medlineplus.gov/genetics/gene/efemp2), [GARD 15804](https://rarediseases.info.nih.gov/assets/singles/15804.json), [DrugMap DISRVQS9](https://drugmap.idrblab.net/data/disease/details/DISRVQS9)

## Reference Validation

Checked with `linkml-reference-validator` 0.5.1.

| Outcome | Count |
| --- | --- |
| References checked | 48 |
| Resolved | 48 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 4 |
| Quoted claims found in source | 2 |
| Quoted claims **not** found in source | 2 |
| References weighed for topical relevance | 48 |
| On topic | 38 |
| Off topic | 0 |

### Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked *abstract only* below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

- `PMID:22440127` *(abstract only)*: "recessively inherited aortic aneurysm"
  - Text part not found as substring: 'recessively inherited aortic aneurysm' (note: only abstract available for PMID:22440127, full text may contain this excerpt)
- `PMID:22943132` *(abstract only)*: "lethal arteriopathy syndrome"
  - Text part not found as substring: 'lethal arteriopathy syndrome' (note: only abstract available for PMID:22943132, full text may contain this excerpt)
